Publications

Letter Epublish 8 citations

PubMed: 35641916 DOI: 10.1186/s11658-022-00341-9

COVID-19 therapies: do we see substantial progress?

Cell Mol Biol Lett 27(1):42

Authors: Lucyna Matusewicz, Marlena Golec, Aleksander Czogalla, Kazimierz Kuliczkowski, Adam Konka, Joanna Zembala-John, Aleksander F Sikorski

Affiliations

  • Department of Cytobiochemistry, Faculty of Biotechnology, University of WrocÅ‚aw, ul. F. Joliot Curie 14a, 50-383, WrocÅ‚aw, Poland.
  • Silesian Park of Medical Technology Kardio-Med Silesia, ul. M. Curie-SkÅ‚odowskiej 10c, 41-800, Zabrze, Poland.
  • Chair and Department of Medicine and Environmental Epidemiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, H. Jordana 19, 41-800, Zabrze, Poland.
  • Acellmed Ltd. M. Curie-SkÅ‚odowskiej 10C, 41-800, Zabrze, Poland.
  • Research and Development Centre, Regional Specialist Hospital, KamieÅ„skiego 73a, 51-154, Wroclaw, Poland.
  • Acellmed Ltd. M. Curie-SkÅ‚odowskiej 10C, 41-800, Zabrze, Poland.

Abstract

The appearance of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its spread all over the world is the cause of the coronavirus disease 2019 (COVID-19) pandemic, which has recently resulted in almost 400 million confirmed cases and 6 million deaths, not to mention unknown long-term or persistent side effects in convalescent individuals. In this short review, we discuss approaches to treat COVID-19 that are based on current knowledge of the mechanisms of viral cell receptor recognition, virus-host membrane fusion, and inhibition of viral RNA and viral assembly. Despite enormous progress in antiviral therapy and prevention, new effective therapies are still in great demand.

MeSH

Biochemistry, Molecular Biology, Biophysics, Physiology, Cells, Therapeutics, Rna, Viral, Coronavirus, Covid-19, Sars-Cov-2

Cited by